GSK secures rights to Syndivia’s ADC asset for prostate cancer
GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 million.
GSK Secures Rights to Syndivia's ADC Asset for Prostate Cancer GSK acquires exclusive rights from Syndivia for an ADC targeting advanced prostate cancer in a deal up to £268 million.
UPS Q3 Earnings Snapshot United Parcel Service Inc. (UPS) reported third-quarter net income of $1.31 billion, with net income of $1.55 per…
Cloud's New Performance Leader: Arm Beats x86 Arm Neoverse-based Graviton4 chips from AWS have set a new standard, outperforming AMD and I…
NYPD Camera Points Directly Into Bedroom, Prompts Lawsuit The NYPD operates a citywide surveillance system using a vast network of public …
Wayfair Q3 Earnings Snapshot Wayfair Inc. reported a loss of $99 million in its third quarter, with a loss of 76 cents per share. E…
Elon Musk's xAI Launches Grok-powered 'Grokipedia' Encyclopedia Elon Musk’s xAI startup has launched Grokipedia, a new open-source encyclo…
AI Tool Analyzes Global Impact of Research Grants A new AI tool, Funding the Frontier (FtF), has been developed to map the impact of resea…
SELUTION DeNovo Trial Results The SELUTION DeNovo randomized clinical trial, presented at TCT 2025 in San Francisco, USA, demonstrates non…
DAZN-Pro League Dispute Continues DAZN's negotiations with Belgian TV operators Proximus and Telenet over carriage of Jupiler Pro League m…
What Your Urine Tests Can Reveal That Your Blood Tests Might Not According to Topoti Mukherjee, Lead Consultant - Nephrology & Kidney Tran…
Operation Food Search Urges St. Louisans to Host Food Drives The Trump administration confirmed that SNAP benefits will not be distributed…